Fluorescence imaging was more accurate than clinical judgement in detecting elevated bacterial loads
$7,660 USD per patient was the estimated cost savings from using fluorescence imaging information
This information avoided the application of cellular tissue products on wounds with high levels of bacteria
Estimated costs of a skin grafting procedure which was avoided based on real-time information from the i:X fluorescence images
Hospital stay (5 days) £2000
Operating room £1500
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s Technology
Breakthrough Designation
MolecuLight i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
©2025
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.